In vivo studies demonstrate that CD200 antibody blockade limits the percentage of tumour-infiltrating MDSCs, but the significance and the mechanisms underlying CD200-CD200R interaction in tumour microenvironment remain to be clarified [108]. The gene discussed is CD200; the disease is neoplasm.